Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use

Merck announced that the FDA has granted approval to its blockbuster anti-PD-1 therapy, Keytruda, for expanded use in cervical cancer. The approval is for Keytruda plus chemoradiotherapy (CRT) for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.